GET DAILY SIGNALSAbeona Therapeutics (ABEO) Shares Decline -52% in 30 Days After Q3 Update and Financing News
Key Takeaways
- Abeona Therapeutics (ABEO) shares fell roughly 52% over the past 30 days, from a closing price of $4.90 on October 12, 2026, to about $2.37 in recent trading.
- The steepest drop came on November 9, 2026, when the stock tumbled more than 37% in a single session after third-quarter results, an acquisition, and a new equity financing were announced together.
- Third-quarter net ZEVASKYN revenue of $13.5 million grew 18% sequentially but missed analyst expectations, while the company disclosed a stock-financed acquisition and a $30 million private placement that raised dilution concerns.
- Over the last quarter, ABEO has fallen from the low-$7 range in mid-August to roughly $2.37, a decline of more than 60% driven by two consecutive revenue shortfalls and financing overhang.
- Investors are now weighing the slower-than-modeled commercial ramp of ZEVASKYN against a broader pipeline that now includes the Phase 3-ready ABO-801 for eosinophilic esophagitis.
- For additional detail on analyst expectations, review Price Targets, Earnings, and Forecast pages for ABEO.
Company Snapshot: Abeona Therapeutics (ABEO)
Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on cell and gene therapies for rare and serious diseases. Its lead product, ZEVASKYN, is an autologous cell-based gene therapy approved by the U.S. Food and Drug Administration for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe genetic skin disorder. The company has also acquired ABO-801, a Phase 3-ready, once-daily oral fluticasone propionate candidate for eosinophilic esophagitis, and is advancing an investigational engineered T-cell therapy targeting PSMA. Abeona competes within the specialized rare-disease gene therapy segment, where launch execution, reimbursement, and manufacturing reliability are closely watched by investors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: -52% Over the Last 30 Days vs. the Quarter
Over the last 30 days, ABEO declined from a closing price of $4.90 on October 12, 2026, to approximately $2.37 in recent trading, a drop of about 52%. The move was not gradual: shares drifted lower through most of October before a sharp, high-volume selloff on November 9, 2026, when the stock fell roughly 37% in one session and closed at $2.54.
The quarterly picture is even steeper. In early-to-mid August, ABEO traded around the low-$7 range before the company's second-quarter results. Since then, the stock has lost more than 60% of its value, reflecting back-to-back quarterly revenue shortfalls, recurring manufacturing-related revenue recognition issues, and new equity financing that increased the share count. From what I see, this kind of compression often highlights execution risks in small-cap biotech.
What Drove the Recent Move in ABEO
The dominant catalyst was the company's third-quarter 2026 update released on November 9, 2026. Abeona reported net ZEVASKYN revenue of $13.5 million, an 18% increase from $11.4 million in the prior quarter, but well below the roughly $18 million consensus estimate. The growth rate also decelerated from 31% sequential growth in the second quarter, signaling a slower commercial ramp than the Street had modeled.
The earnings announcement was paired with two additional disclosures that compounded selling pressure. First, Abeona announced the acquisition of ABO-801, a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals for $20 million in stock with no upfront cash. Second, the company entered into a $30 million private placement involving roughly 6.4 million shares plus pre-funded warrants. Because the acquisition was paid entirely in equity and accompanied by a dilutive financing, investors reacted negatively to the combined share-count increase, even as management framed the transaction as a capital-efficient way to add a late-stage asset.
Revenue-recognition friction also weighed on sentiment. For the second consecutive quarter, a completed treatment could not be billed because of a manufacturing specification issue, and the company noted that its planned annual manufacturing shutdown would keep treatment timing variable into early 2027.
Broader Drivers Behind the Quarterly Decline
The multi-month decline traces back to the second-quarter 2026 report in mid-August, when ZEVASKYN revenue of $11.4 million missed expectations and triggered a double-digit selloff. Since then, investors have grown more cautious about the pace of the ZEVASKYN launch, which has been affected by patient-scheduling variability, manufacturing batch issues, and the gradual activation of qualified treatment centers.
Although the company expanded its treatment network to eight sites and secured New Technology Add-On Payment status effective October 1, 2026, the recurring billing disruptions and slower revenue recognition have kept a lid on the stock. The November acquisition and private placement added a new layer of dilution concerns, reinforcing the broader risk-off sentiment toward small-cap biotech names. Abeona ended the third quarter with $134.9 million in cash and short-term investments, a balance that was supplemented by the $30 million private placement.
Key Factors to Watch Going Forward
Going forward, the key variables for ABEO will be the trajectory of ZEVASKYN revenue and the number of revenue-recognized treatments each quarter, particularly as the company works through its manufacturing shutdown and navigates reimbursement processes. Investors will also monitor dilution from the recent equity transactions, the company's cash runway, and whether gross margins improve as manufacturing utilization rises.
On the pipeline side, attention will turn to the planned Phase 3 study for ABO-801, including the outcome of the anticipated FDA Type C meeting on trial design and the timing of study initiation. Milestone and royalty opportunities from partnered programs also remain relevant. As always, execution risk, regulatory decisions, and broader biotech sector sentiment will influence the stock's direction. These factors are informational in nature and should not be taken as investment recommendations. I’m watching this closely as the company moves through its manufacturing cycle.
Exploring Tickeron’s AI Tools for Biotech Analysis
In my own research process, I often rely on Tickeron’s AI Trend Prediction Engine to help contextualize price action in names like ABEO. The platform uses historical patterns and current data to flag potential scenarios, which can be useful when sorting through volatile sectors. It is not a replacement for fundamental work, but it adds another layer of perspective when evaluating catalysts and risks. The tool is available at https://tickeron.com/stock-tpe/.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
ABEO in -41.13% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABEO declined for three days, in 270 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In 75 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ABEO turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for ABEO moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for ABEO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.862) is normal, around the industry mean (3.498). P/E Ratio (-3.446) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ABEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry Biotechnology
Advertisement